Publication Author: Urban_Nicole

• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15;68(8):2581-6. doi: 10.1158/0008-5472.CAN-08-0088.

  rakerr2

  April 15, 2008

• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

  Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28;451(7182):11

  rakerr2

  February 28, 2008

• Effects of blood collection conditions on ovarian cancer serum markers.

  Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N. Effects of blood collection conditions on ovarian cancer serum markers. PLoS One. 2007 Dec 5;2(12):e1281.

  rakerr2

  December 5, 2007

• Use of high density antibody arrays to validate and discover cancer serum biomarkers.

  Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol. 2007 Dec;1(3):313-20. doi: 10.1016/j.molonc.2007.08.

  rakerr2

  December 1, 2007

• Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.

  Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett. 2007 Oct 8;255(2):263-74. Epub 2007 Jun 7.

  rakerr2

  October 8, 2007

• Changes in cancer worry associated with participation in ovarian cancer screening.

  Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Lowe KA, Urban N. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007 Sep;16(9):814-20.

  rakerr2

  September 1, 2007

• Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.

  McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8.

  rakerr2

  August 1, 2007

• Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

  Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007 Mar 8;247(1):130-6. Epub 2006 May 4.

  rakerr2

  March 8, 2007

• Development of an ovarian cancer symptom index: possibilities for earlier detection.

  Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007 Jan 15;109(2):221-7.

  rakerr2

  January 15, 2007

• Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.

  Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods. 2006 Dec 20;317(1-2):132-43. Epub 2006 Oct 30.

  rakerr2

  December 20, 2006